Provided by Tiger Trade Technology Pte. Ltd.

CHINARES PHARMA

4.480
+0.0100.22%
Volume:7.25M
Turnover:32.28M
Market Cap:28.15B
PE:5.97
High:4.495
Open:4.470
Low:4.430
Close:4.470
52wk High:6.336
52wk Low:4.211
Shares:6.28B
HK Float Shares:6.28B
Volume Ratio:0.95
T/O Rate:0.12%
Dividend:0.22
Dividend Rate:4.86%
EPS(LYR):0.750
ROE:8.32%
ROA:2.64%
PB:0.46
PE(LYR):5.97
PS:0.09

Loading ...

Jiang Zhong Pharmaceutical's Profit Jumps 15% in 2025

MT Newswires Live
·
Mar 20

China Resources Pharma (03320.HK) Subsidiary Dong-E-E-Jiao Posts 2025 Net Profit of RMB 1.74 Billion, Up 11.66%

Bulletin Express
·
Mar 19

China Resources Pharmaceutical Group Ltd - FY Revenue for Dong-E-E-Jiao RMB6.70 Bln

THOMSON REUTERS
·
Mar 19

CR Pharma (03320) Subsidiary KPC Records 46% Profit Decline in FY 2025, Revenue Falls 22%, Announces RMB 0.18 Cash Dividend Per Share

Bulletin Express
·
Mar 19

BRIEF-China Resources Pharmaceutical Says KPC Pharmaceuticals Proposes Dividend Of Rmb1.80 per 10 Shares

Reuters
·
Mar 19

China Resources Pharmaceutical - Kpc Pharmaceuticals FY Revenue RMB6.58 Bln

THOMSON REUTERS
·
Mar 19

China Resources Pharmaceutical - Kpc Pharmaceuticals Proposed to Distribute Cash Dividend of RMB1.80 for Every 10 Shares

THOMSON REUTERS
·
Mar 19

CR Double-Crane net assets attributable to shareholders rise 11.78% to RMB11.63 billion in 2025

Reuters
·
Mar 19

China Resources Pharmaceutical (03320) Discloses FY2025 Results of Subsidiary Tasly Pharmaceutical: Revenue Down 3.08%, Core Net Profit Up 15.63%

Bulletin Express
·
Mar 19

CHINARES PHARMA (03320) Reports Tasly Pharmaceutical's 2025 Net Profit Attributable to Shareholders at RMB 1.105 Billion, Up 15.63%

Stock News
·
Mar 19

CR Sanjiu affiliate Tasly Pharmaceutical reports 2025 net profit of RMB1.1 billion, up 15.63%

Reuters
·
Mar 19

CHINARES PHARMA (03320): Subsidiary CR Jiangzhong Delivers 15.03% Profit Growth in FY 2025, Proposes RMB0.88 Dividend per Share

Bulletin Express
·
Mar 19

China Resources Pharmaceutical - FY Revenue of Cr Jiangzhong Pharmaceutical RMB4.22 Bln

THOMSON REUTERS
·
Mar 19

CR Jiangzhong net profit attributable to shareholders rises 15.03% to RMB 0.91 billion

Reuters
·
Mar 19

China Resources Pharma Divests Tianmai Biotech Stake After Years of Unsuccessful Oral Insulin Bets

Deep News
·
Mar 17

BRIEF-China Resources Pharmaceutical Discloses Potential Disposal Of Tianmai Biotechnology

Reuters
·
Mar 16

CHINARES PHARMA (03320) Considers RMB0.51 Billion Sale of 5.88% Stake in Tianmai Biotechnology

Bulletin Express
·
Mar 16

China Resources Pharma's Investment Arm to Divest 5.88% Stake in Tianmai Biotech

Stock News
·
Mar 16

China Resources Pharma launches tender to sell 5.88% stake in Tianmai Biotechnology for at least RMB0.51 billion

Reuters
·
Mar 16

China Resources Pharmaceutical Group Ltd - Initial Minimum Listing Price of Approximately RMB0.51 Bln

THOMSON REUTERS
·
Mar 16